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Background
IgGs that possess a2,6-sialylated Fc-glycans are thought
to be responsible for the anti-inflammatory properties of
intravenous immunoglobulins (IVIGs) [1], through a
mechanism which has not been elucidated yet. The
impact of this sialylation on the classic IgG’s effector
functions also remains unclear [2,3]. The understanding
of these mechanisms has been impeded by the heteroge-
neity of the sialylated glycan species together with the
relative rarity of a2,6-sialylated IgGs.
N-glycan sialylation is a post-translational modifica-
tion where a sialic acid (SA) residue is added to the
terminal galactose residue (Gal) of a growing glycan
chain. The SA type (NANA or NGNA), the nature of
the linkage between the SA and the Gal (a2,3 or a2,6),
or the number of glycan antennae being sialylated, may
vary according to the IgG subtype, the host cell in
which it is expressed and the cell culture environment.
A closer attention must thus be paid to the precise sia-
lylation profiles leading to the reduced ADCC activity
and to the gain of anti-inflammatory properties.
In humans, 10 to 15% of the circulating IgG1s are sialy-
lated, carrying mostly complex di-antennary glycans with
two Gal and one a2,6-linked SA residue (G2FS(6)1,
where G stands for galactose, F for fucose and S(6) for
a2,6SA). Most of the therapeutic monoclonal antibodies
(mabs) are produced in Chinese hamster ovary (CHO)
cells, which have a glycosylation machinery close to that
of humans, but possess only a2,3-sialyltransferases (ST3)
whereas humans have both a2,3- and a2,6-sialyltrans-
ferases. The Fc domain of mabs produced in CHO typi-
cally possesses N-glycans with low galactosylation and
very low sialylation (0-2% of a2,3-sialylated glycans).
In this study, we show that the a2,6-sialylation of
IgG1’s Fc domain can be efficiently achieved by the
transient coexpression of the human b1,4-galactosyl-
transferase 1 (GT) and a2,6-sialyltransferase 1 (ST6) in
CHO cells, whereas the expression of one or the other
glycosyltransferase alone does not significantly improve
sialylation [4]. The process allows for the production of
milligrams of human-like sialylated mabs within two
weeks. We present a panel of four orthogonal assays for
the fine characterization of the mabs’ glycoprofile that
are in very good agreement with each other.
Experimental approach
CHO cells in suspension were transfected with polyplexes
composed of polyethylenimine and plasmids encoding the
mab and the enzymes. The proteins were expressed transi-
ently, or stable pools were obtained following MSX selec-
tion in glutamine free medium. The mabs were purified
on protein A resin from the supernatants after four days
to avoid sialylation degradation (potentially caused by siali-
dases, pH and ammonia levels increase in late culture).
The glycoprofiles were characterized through a set of four
assays: lectin-blotting, capillary isoelectric focusing (cIEF),
liquid chromatography coupled to electrospray ionisation
mass spectrometry (LC-ESI-MS) and hydrophilic interac-
tion liquid chromatography (HILIC). The relative glycan
abundances obtained by LC-ESI-MS and HILIC correlated
very well (Pearson coefficient 0.96). The evaluation of SA
linkage type was accomplished by HILIC analyses after
a2,3-specific or broad range sialidases treatment.
Results and discussion
The transient expression of both GT and ST6 resulted in
IgG1s where G2FS(6)1 was predominant (Figure 1), and
88% of the SA were of a2,6 type. 75% of the glycan
branches were galactosylated and 25% sialylated, in com-
parison with 23% and 1% respectively in IgG1s expressed
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alone. In contrast, the co-expression of GT or ST6 led to
less than 5% of sialylated glycan antennae. While the low
galactosylation level in IgG1+ST6 can explain this result, it
is surprising in the case of IgG1+GT where 70% of the
branches were galactosylated.
Since heavily sialylated proteins were produced in
CHO cells in our laboratory and others without cell
engineering, we hypothesized that the glycan interac-
tions with the Fc amino acids were limiting the access
of ST3 to the galactosylated glycans. We thus expressed
a mutated version of our IgG1, IgG1F243A, where the
F243-glycan interaction is abolished, increasing the gly-
can exposition to the glycosyltransferases. Indeed,
IgG1F243A was well galactosylated and sialylated: Gal
and SA were present on 74% and 43% of the branches
respectively. Upon GT expression, >95% of the antennae
were galactosylated but the proportion of sialylated
branches decreased to 33%. Therefore, the F243A muta-
tion, while enhancing galactosylation and sialylation in
general, did not promote endogenous sialylation of the
Gal available in IgG1F243A+GT. The poor accessibility
of the glycan to ST3 in the wild-type Fc was thus not
sufficient to explain the lack of a2,3-sialylation in IgG1
+GT, opening questions about the ST3 ability to use
Gal provided by the human GT.
With this approach, the IgG1s were produced at
yields around 15 mg/L. In order to reach yields closer
to 200 mg/L, stable pools of CHO cells expressing GT,
ST6 and an IgG1 were selected. However, the high
mab productivity was achieved to the detriment of the
sialylation level. Transfection and selection parameters
were thus modified (new ST6 coding plasmid,
increased proportion in the transfection mix) to reach
high sialylation levels, along with mab concentrations
around 100 mg/L.
Our method allows the fast production of milligrams
of IgGs with a human-like Fc-sialylation, providing
material for further functional studies, and also initiating
the development of a recombinant substitute for anti-
inflammatory IVIGs. The association of Fc/2 analysis by
LC-ESI-MS with glycan analysis by HILIC constitutes a
highly reliable platform for the fine characterization of
antibodies’ glycoprofiles.
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Figure 1 LC-ESI-MS molecular weight profiles obtained for Fc/2 glycopeptides show that the co-expression of the Trastuzumab (TZM)
with GT and ST6 yields glycoprofiles where G2FS1 is predominant.
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